
Focus 3:484-488, Summer 2005
© 2005 American Psychiatric Association
Testing an APA Practice Guideline: SymptomTargeted Medication Utilization for Patients With Borderline Personality Disorder
John M. Oldham, M.D.,
Donna S. Bender, Ph.D.,
Andrew E. Skodol, M.D.,
Ingrid R. Dyck, M.P.H.,
Charles A. Sanislow, Ph.D.,
Shirley Yen, Ph.D.,
Carlos M. Grilo, Ph.D.,
M. Tracie Shea, Ph.D.,
Mary C. Zanarini, Ed.D.,
John G. Gunderson, M.D., and
Thomas H. McGlashan, M.D.
Background: The goal of this study was to test whether the use of psychotropic medication treatment for borderline personality disorder (BPD) was consistent with proposals in the recently published American Psychiatric Associations Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. Method: Medication utilization by patients with BPD was assessed prospectively over a 2-year period prior to the publication of the Guideline. Three BPD symptom clusterscognitive-perceptual, affective dysregulation, and impulsive-behavioral dyscontrolalong with demographic and functioning variables were used to predict the use of five classes of medication. Results: Symptoms of impulsive-behavioral dyscontrol significantly predicted use of both neuroleptics and anticonvulsants. Cognitive-perceptual symptoms were inversely related to anticonvulsant use. Conclusion: While some pre-Guideline medication practices with BPD patients were consistent with the recommended algorithms, physicians may also have been influenced by a variety of considerations, including level of functional impairment and the presence of comorbid Axis I conditions.
(Reprinted with permission from the
Journal of Psychiatric Practice 2004; 10(3):156161)
Get information about faster international access.
a>
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|